Dolutegravir plus rilpivirine: benefits beyond viral suppression
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000029252
Abstract: Abstract Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and… read more here.
Keywords: cd4 cd8; cell count; cell; plus rilpivirine ... See more keywords